Enrollment begins for phase 2 trial of Betaliq glaucoma drop
Betaliq has enrolled the first patient in a phase 2 trial investigating BTQ-1901 and BTQ-1902 for the treatment of glaucoma or ocular hypertension, according to a press release.
The multicenter, double-masked, parallel-group, dose-ranging study will take place over 12 weeks and aims to enroll about 240 patients. The trial will investigate the safety and efficacy of BTQ-1901 (0.5% and 1% concentrations) and BTQ-1902 ophthalmic suspensions compared with timolol ophthalmic solution 0.5% in adults with elevated IOP due to primary open-angle glaucoma or ocular hypertension. IOP will be compared after 2, 6 and 12 weeks of treatment.
“We are very excited to advance our products into the clinic. BTQ-1901 and BTQ-1902 are based on Novaliq’s EyeSol technology that offers important advantages over traditional eye drop technology, including a drop size approximately 25% of the size of water-based drops,” Barry Butler, president and CEO of Betaliq, said in the release.